Study: Epo is well tolerated in neonates with HIE

11/16/2012 | Medscape (free registration)

Early trial data showed erythropoietin, given in addition to hypothermia treatment, was well tolerated and may be neuroprotective for neonates with hypoxic-ischemic encephalopathy. Researchers at the University of California, San Francisco, said they plan to do a large randomized trial of Epo that will follow infants for two years to evaluate neurologic outcomes.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Regulatory Analyst
Delta Dental
Alpharetta, GA
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA